Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6373489 | 0.88 | SIGMAR1 (0.55) | DRD2SIGMAR1PARP1HTR1AHTR7 | |
| SCHEMBL6367626 | 0.88 | SIGMAR1 (0.54) | DRD2SIGMAR1 | |
| SCHEMBL6368144 | 0.87 | SIGMAR1 (0.55) | DRD2SIGMAR1PARP1HTR1A | |
| SCHEMBL6373296 | 0.87 | DRD2 (0.61) | DRD2SIGMAR1PARP1HTR1A | |
| SCHEMBL6374778 | 0.86 | SIGMAR1 (0.58) | DRD2SIGMAR1HTR1A | |
| SCHEMBL6374865 | 0.86 | PARP1 (0.48) | DRD2SIGMAR1PARP1HTR7 | |
| SCHEMBL8010714 | 0.84 | SIGMAR1 (0.72) | DRD2SIGMAR1MAPK1PARP1MEN1 | |
| SCHEMBL6437335 | 0.84 | SIGMAR1 (0.58) | DRD2SIGMAR1PARP1MEN1KMT2A | |
| SCHEMBL6367451 | 0.83 | DRD2 (0.44) | DRD2SIGMAR1CYP2D6THPO | |
| SCHEMBL7964089 | 0.81 | DRD2 (0.64) | DRD2SIGMAR1PARP1HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1469854-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003063874-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | DRD2 1026/4885SIGMAR1 3797/4885MAPK1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.